Ersentilid
| |
| Nazivi | |
|---|---|
| IUPAC naziv
N-[4-[2-Hidroksi-3-[2-(4-imidazol-1-ilfenoksi)etilamino]propoksi]fenil]metansulfonamid
| |
| Identifikacija | |
3D model (Jmol)
|
|
| ChemSpider | |
| |
| Svojstva | |
| C21H26N4O5S | |
| Molarna masa | 446,52 g·mol−1 |
Ukoliko nije drugačije napomenuto, podaci se odnose na standardno stanje materijala (na 25 °C [77 °F], 100 kPa). | |
| Reference infokutije | |
Ersentilide je antagonist beta adrenergijskog receptora.[3]
Reference
[уреди | уреди извор]- ^ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today. 15 (23-24): 1052—7. PMID 20970519. doi:10.1016/j.drudis.2010.10.003.
- ^ Evan E. Bolton; Yanli Wang; Paul A. Thiessen; Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry. 4: 217—241. doi:10.1016/S1574-1400(08)00012-1.
- ^ Lombardi, F; Terranova, P (2006). „Pharmacological treatment of atrial fibrillation: Mechanisms of action and efficacy of class III drugs”. Current Medicinal Chemistry. 13 (14): 1635—53. PMID 16787210. doi:10.2174/092986706777441940.